Phase I Study of MLN8237 in Combination With Cetuximab and Definitive Radiation in Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck.
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 02 Aug 2017
At a glance
- Drugs Alisertib (Primary) ; Cetuximab (Primary)
- Indications Head and neck cancer
- Focus Adverse reactions
- 18 Jul 2016 Status changed from completed to active, no longer recruiting.
- 06 Mar 2012 New trial record